These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 36377297)

  • 21. High Neutralizing Antibody Levels Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron BA.1 and BA.2 After UB-612 Vaccine Booster.
    Guirakhoo F; Wang S; Wang CY; Kuo HK; Peng WJ; Liu H; Wang L; Johnson M; Hunt A; Hu MM; Monath TP; Rumyantsev A; Goldblatt D
    J Infect Dis; 2022 Oct; 226(8):1401-1406. PubMed ID: 35723969
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A booster dose of Delta × Omicron hybrid mRNA vaccine produced broadly neutralizing antibody against Omicron and other SARS-CoV-2 variants.
    Lee IJ; Sun CP; Wu PY; Lan YH; Wang IH; Liu WC; Yuan JP; Chang YW; Tseng SC; Tsung SI; Chou YC; Kumari M; Lin YS; Chen HF; Chen TY; Lin CC; Chiu CW; Hsieh CH; Chuang CY; Cheng CM; Lin HT; Chen WY; Hsu FF; Hong MH; Liao CC; Chang CS; Liang JJ; Ma HH; Chiang MT; Liao HN; Ko HY; Chen LY; Ko YA; Yu PY; Yang TJ; Chiang PC; Hsu ST; Lin YL; Lee CC; Wu HC; Tao MH
    J Biomed Sci; 2022 Jul; 29(1):49. PubMed ID: 35799178
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac, ChAdox1 nCov-19 and BNT162b2 plus BNT162b2 booster vaccination: An open-label randomized study in healthy Thai adults.
    Niyomnaitham S; Quan Toh Z; Wongprompitak P; Jansarikit L; Srisutthisamphan K; Sapsutthipas S; Jantraphakorn Y; Mingngamsup N; Licciardi PV; Chokephaibulkit K
    Hum Vaccin Immunother; 2022 Nov; 18(6):2091865. PubMed ID: 35816053
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A comprehensive analysis of the efficacy and effectiveness of COVID-19 vaccines.
    He X; Su J; Ma Y; Zhang W; Tang S
    Front Immunol; 2022; 13():945930. PubMed ID: 36090988
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibody evasion of SARS-CoV-2 Omicron BA.1, BA.1.1, BA.2, and BA.3 sub-lineages.
    Ai J; Wang X; He X; Zhao X; Zhang Y; Jiang Y; Li M; Cui Y; Chen Y; Qiao R; Li L; Yang L; Li Y; Hu Z; Zhang W; Wang P
    Cell Host Microbe; 2022 Aug; 30(8):1077-1083.e4. PubMed ID: 35594867
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Booster BNT162b2 COVID-19 Vaccination Increases Neutralizing Antibody Titers Against the SARS-CoV-2 Omicron Variant in Both Young and Elderly Adults.
    Um J; Choi YY; Kim G; Kim MK; Lee KS; Sung HK; Kim BC; Lee YK; Jang HC; Bang JH; Chung KH; Oh MD; Park JS; Jeon J
    J Korean Med Sci; 2022 Mar; 37(9):e70. PubMed ID: 35257525
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
    Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ;
    Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A fourth dose of Omicron RBD vaccine enhances broad neutralization against SARS-CoV-2 variants including BA.1 and BA.2 in vaccinated mice.
    Zhou B; Song S; Guo H; Zhou X; Fan Q; Liu W; Cheng L; Ge X; Ju B; Zhang Z
    J Med Virol; 2022 Aug; 94(8):3992-3997. PubMed ID: 35474319
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
    Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
    J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pivoting to protein: the immunogenicity and safety of protein-based NVX-CoV2373 as a heterologous booster for inactivated and viral vector COVID-19 vaccines.
    Marchese AM; Kalkeri R; Vadivale M; Suntronwong N; Toback S; Poovorawan Y
    Expert Rev Vaccines; 2023; 22(1):620-628. PubMed ID: 37386785
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Three doses of an inactivation-based COVID-19 vaccine induces cross-neutralizing immunity against the SARS CoV-2 Omicron variant.
    Yu X; Qi X; Cao Y; Li P; Lu L; Wang P; Feng Y; Yang J; Wei H; Guo L; Sun M; Liu Q; Lv J; Feng Y
    Emerg Microbes Infect; 2022 Dec; 11(1):749-752. PubMed ID: 35176972
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sequential immunization with SARS-CoV-2 RBD vaccine induces potent and broad neutralization against variants in mice.
    Song S; Zhou B; Cheng L; Liu W; Fan Q; Ge X; Peng H; Fu YX; Ju B; Zhang Z
    Virol J; 2022 Jan; 19(1):2. PubMed ID: 34983583
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rational design of a booster vaccine against COVID-19 based on antigenic distance.
    Hu YF; Yuen TT; Gong HR; Hu B; Hu JC; Lin XS; Rong L; Zhou CL; Chen LL; Wang X; Lei C; Yau T; Hung IF; To KK; Yuen KY; Zhang BZ; Chu H; Huang JD
    Cell Host Microbe; 2023 Aug; 31(8):1301-1316.e8. PubMed ID: 37527659
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness of the third dose of BNT162b2 vaccine on neutralizing Omicron variant in the Japanese population.
    Kawasuji H; Morinaga Y; Tani H; Saga Y; Kaneda M; Murai Y; Ueno A; Miyajima Y; Fukui Y; Nagaoka K; Ono C; Matsuura Y; Niimi H; Yamamoto Y
    J Infect Chemother; 2022 Sep; 28(9):1273-1278. PubMed ID: 35691864
    [TBL] [Abstract][Full Text] [Related]  

  • 35. mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant.
    Gruell H; Vanshylla K; Tober-Lau P; Hillus D; Schommers P; Lehmann C; Kurth F; Sander LE; Klein F
    Nat Med; 2022 Mar; 28(3):477-480. PubMed ID: 35046572
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern.
    Hawman DW; Meade-White K; Archer J; Leventhal SS; Wilson D; Shaia C; Randall S; Khandhar AP; Krieger K; Hsiang TY; Gale M; Berglund P; Fuller DH; Feldmann H; Erasmus JH
    Elife; 2022 Feb; 11():. PubMed ID: 35191378
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Heterologous immunization with adenovirus vectored and inactivated vaccines effectively protects against SARS-CoV-2 variants in mice and macaques.
    He Q; Mao Q; Zhang J; Gao F; Bai Y; Cui B; Liu J; An C; Wang Q; Yan X; Yang J; Song L; Song Z; Liu D; Yuan Y; Sun J; Zhao J; Bian L; Wu X; Huang W; Li C; Wang J; Liang Z; Xu M
    Front Immunol; 2022; 13():949248. PubMed ID: 36059554
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Humoral and cellular response induced by a second booster of an inactivated SARS-CoV-2 vaccine in adults.
    Méndez C; Peñaloza HF; Schultz BM; Piña-Iturbe A; Ríos M; Moreno-Tapia D; Pereira-Sánchez P; Leighton D; Orellana C; Covarrubias C; Gálvez NMS; Soto JA; Duarte LF; Rivera-Pérez D; Vázquez Y; Cabrera A; Bustos S; Iturriaga C; Urzua M; Navarrete MS; Rojas Á; Fasce RA; Fernández J; Mora J; Ramírez E; Gaete-Argel A; Acevedo M; Valiente-Echeverría F; Soto-Rifo R; Weiskopf D; Grifoni A; Sette A; Zeng G; Meng W; ; González-Aramundiz JV; González PA; Abarca K; Melo-González F; Bueno SM; Kalergis AM
    EBioMedicine; 2023 May; 91():104563. PubMed ID: 37099842
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Omicron Booster in Ancestral Strain Vaccinated Mice Augments Protective Immunities Against Both Delta and Omicron Variants.
    Jia L; Zhou Y; Li S; Zhang Y; Yan D; Wang W; Zhang W; Wan Y; Qiu C
    Front Immunol; 2022; 13():897879. PubMed ID: 35874751
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SARS-CoV-2 Omicron variants: burden of disease, impact on vaccine effectiveness and need for variant-adapted vaccines.
    Pather S; Madhi SA; Cowling BJ; Moss P; Kamil JP; Ciesek S; Muik A; Türeci Ö
    Front Immunol; 2023; 14():1130539. PubMed ID: 37287979
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.